Literature DB >> 2121818

The mechanism of the effect of combination treatment with clomiphene and bromocriptine in patients with normoprolactinemic anovulation.

T Yasui1, M Irahara, K Shisukawa, K Azuma, T Aono.   

Abstract

The combination treatment with bromocriptine and clomiphene citrate was applied to 11 normoprolactinemic anovulatory patients who did not respond to clomiphene citrate alone. This combination treatment restored ovulation in 8 of these patients (72.7%). Conception was observed in 2 patients (18.1%) out of 11. The patients who responded to combination treatment showed a significant increase in the serum level of estradiol in the preovulatory phase, of progesterone in the mid-luteal phase, and a significant decrease of serum prolactin. They also showed significant increase in the frequency of luteinizing hormone (LH) pulsatility on day 12 of the cycle from 1.38 +/- 0.86 to 3.75 +/- 0.83 pulses/4h. The 3 patients who did not respond to combination treatment showed no increase in the serum level of estradiol or progesterone, but showed increase in the frequency of LH pulsatility in spite of continuous anovulation. These results indicate that the combination treatment with bromocriptine and clomiphene citrate is effective for treatment of patients with normoprolactinemic anovulation who do not respond to clomiphene alone, and suggest that the mechanism of the effect of combination treatment is related to an increase in the frequency of LH pulsatility caused by bromocriptine, which in turn stimulates follicular maturation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121818     DOI: 10.1007/bf03348623

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  Bromocriptine increases plasma estradiol-17 beta concentration in amenorrhea patients with normal serum prolactin.

Authors:  M Seppälä; H A Unnérus; E Hirvonen; T Ranta
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

3.  Effects of dopamine infusion on pituitary hormone secretion in humans.

Authors:  H Leblanc; G C Lachelin; S Abu-Fadil; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1976-09       Impact factor: 5.958

4.  Restoration of oestrogen positive feedback effect on LH release by bromocriptine in hyperprolactinaemic patients with galactorrhoea-amenorrhoea.

Authors:  T Aono; A Miyake; T S Yasuda; K Koike; K Kurachi
Journal:  Acta Endocrinol (Copenh)       Date:  1979-08

5.  Bromocryptine-cyclofenil associated therapy: an effective and safe mode of treatment of female normoprolactinemic infertility.

Authors:  G Moggi; O Giampietro; I De Luca Brunori
Journal:  Acta Eur Fertil       Date:  1983 Sep-Oct

6.  Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms.

Authors:  R J Santen; C W Bardin
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

7.  Induction of menstruation with bromocryptine in patients with euprolactinemic amenorrhea.

Authors:  G Tolis; F Naftolin
Journal:  Am J Obstet Gynecol       Date:  1976-10-15       Impact factor: 8.661

8.  Dopaminergic regulation of gonadotropin levels and pulsatility in normal women.

Authors:  A N Andersen; C Hagen; P Lange; S Boesgaard; H Djursing; E Eldrup; S Micic
Journal:  Fertil Steril       Date:  1987-03       Impact factor: 7.329

9.  Induction of ovulation in patients with normoprolactinemic amenorrhea by combined therapy with bromocriptine and clomiphene.

Authors:  K Koike; T Aono; A Miyake; H Tsutsumi; K Matsumoto; K Kurachi
Journal:  Fertil Steril       Date:  1981-02       Impact factor: 7.329

10.  Dopaminergic mechanisms and luteinizing hormone (LH) secretion. II. Differential effects of dopamine and bromocriptine on LH release in normal women.

Authors:  W H Martin; A D Rogol; D L Kaiser; M O Thorner
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.